HF
DMAC icon

HRT Financial’s DiaMedica Therapeutics DMAC Stock Holding History

HRT Financial’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56,703
Closed -$214K – 2812
2025
Q1 		$214K Buy
+56,703
New +$324K ﹤0.01% 1978
2022
Q4 		– Sell
-10,441
Closed -$12K – 2596
2022
Q3 		$12K Buy
+10,441
New +$16.3K ﹤0.01% 2521

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial's DMAC Position: Q2 2025 in Review

HRT Financial sold out of DiaMedica Therapeutics (DMAC) in Q2 2025, closing a stake of 56,703 shares — an estimated $214K sold.

HRT Financial first reported a position in DMAC in Q3 2022 and held it in 2 quarters. The position peaked at $214K in Q1 2025. 58 funds tracked by Wall St. Rank hold DMAC as of Q2 2025.

  • HRT Financial reported no remaining DiaMedica Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 56,703 DiaMedica Therapeutics shares in Q2 2025, an estimated $214K.
  • HRT Financial first reported a position in DiaMedica Therapeutics in Q3 2022 and held it in 2 quarters.
  • HRT Financial's DiaMedica Therapeutics position peaked at $214K in Q1 2025.
  • 58 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.